1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,680 | 2,860 | 12:48 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - WHOLLY-OWNED SUBSIDIARY PASSING FDA ON-SITE INSPECTION | 2 | HKEx | ||
| Di | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE CONVENING OF THE 2025 THIRD QUARTERLY ... | 1 | HKEx | ||
| 17.10. | Junshi Biosciences gets FDA approval for lung cancer trial | 2 | Investing.com | ||
| SHANGHAI JUNSHI BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 17.10. | Junshi Biosciences Announces FDA's Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients | 359 | GlobeNewswire (Europe) | SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen | |
| 16.10. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - FDA APPROVAL OF INVESTIGATIONAL NEW DRUG APPLICATION FOR PHASE II/III CLINICAL STUDY OF JS207 FOR THE NEOADJUVANT ... | - | HKEx | ||
| 15.10. | JUNSHI BIO (01877): DATE OF BOARD MEETING | - | HKEx | ||
| 10.10. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON PROGRESS OF THE INCREASE IN SHAREHOLDING ... | 1 | HKEx | ||
| 29.09. | JUNSHI BIO (01877): ADJUSTMENTS TO THE LIST OF PARTICIPANTS AND THE NUMBER OF A SHARE OPTIONS TO BE GRANTED AND THE FIRST GRANT OF A SHARE OPTIONS TO ... | 2 | HKEx | ||
| 29.09. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD. ANNOUNCEMENT ON EXTERNAL INVESTMENT AND RELATED PARTY TRANSACTION | 1 | HKEx | ||
| 29.09. | JUNSHI BIO (01877): POLL RESULTS OF THE 2025 FIRST EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 29.09. | JUNSHI BIO (01877): ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTOR CHANGE IN COMPOSITION OF THE REMUNERATION AND APPRAISAL COMMITTEE AND THE NOMINATION ... | 3 | HKEx | ||
| 29.09. | JUNSHI BIO (01877): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 29.09. | JUNSHI BIO (01877): ARTICLES OF ASSOCIATION | - | HKEx | ||
| 26.09. | JUNSHI BIO (01877): 2025 INTERIM REPORT | - | HKEx | ||
| 25.09. | UBS stuft Shanghai Junshi Biosciences wegen hoher Bewertung auf "Neutral" herab | 1 | Investing.com Deutsch | ||
| 25.09. | UBS downgrades Shanghai Junshi Biosciences stock to Neutral on valuation | 1 | Investing.com | ||
| 15.09. | JUNSHI BIO (01877): SUPPLEMENTAL FORM OF PROXY FOR THE 2025 FIRST EXTRAORDINARY GENERAL MEETING TO BE HELD ON MONDAY, 29 SEPTEMBER 2025 | 2 | HKEx | ||
| 15.09. | JUNSHI BIO (01877): SUPPLEMENTAL NOTICE OF EXTRAORDINARY GENERAL MEETING | 2 | HKEx | ||
| 15.09. | JUNSHI BIO (01877): SUPPLEMENTAL CIRCULAR PROPOSED GRANT OF H SHARE OPTIONS TO EXECUTIVE DIRECTORS AND ASSOCIATES OF SUBSTANTIAL SHAREHOLDERS AND SUPPLEMENTAL ... | 1 | HKEx | ||
| 15.09. | JUNSHI BIO (01877): ADJOURNMENT OF EXTRAORDINARY GENERAL MEETING | - | HKEx |
1 2 3 4 Weiter >>
71 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 48,550 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 | SAN DIEGO, Oct. 13, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| ARCELLX | 84,07 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 6,590 | 0,00 % | Ventyx Biosciences: NBC feiert Daten-Knall und +928% in 6 Monaten | Der Party-Herbst reißt nicht ab: Nach dem Tenbagger Minerva explodieren im No Brainer Club die nächsten Kurs-Granaten. Eine davon ist die Aktie von Ventyx Biosciences. Die Ventyx-Aktie hatte der No... ► Artikel lesen | |
| ADMA BIOLOGICS | 15,250 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 57,76 | 0,00 % | Mizuho startet Coverage für Kymera Therapeutics mit "Outperform" | ||
| HARMONY BIOSCIENCES | 29,600 | 0,00 % | Harmony Biosciences Rises 10.6% On Strong Q3 WAKIX Results And Upgraded Guidance | ||
| NUVALENT | 90,89 | 0,00 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| TANGO THERAPEUTICS | 7,510 | 0,00 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces $225 Million Financing | BOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
| NURIX THERAPEUTICS | 10,400 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Initiates DAYBreak Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia | 600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,720 | 0,00 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings | ||
| 89BIO | 14,800 | 0,00 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
| EVOTEC | 6,950 | +1,22 % | Übernahme von Vidac Pharma und Evotec? 400 Mrd. USD bei Pfizer, Merck und Co im Feuer! | Alarm bei Big Pharma! Donald Trump scheint bei der Reduzierung von Medikamentenpreisen ernst zu machen. Gleichzeitig laufen Patente bei Blockbustern aus und ein 400 Mrd. USD Umsatzausfall droht. Pfizer... ► Artikel lesen | |
| COGENT BIOSCIENCES | 14,840 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib | Detailed results from bezuclastinib's positive SUMMIT trial evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis planned for presentation at upcoming scientific conference this... ► Artikel lesen | |
| MAZE THERAPEUTICS | 29,900 | 0,00 % | Maze Therapeutics files to sell 9.23M shares of common stock for holders | ||
| PRAXIS PRECISION MEDICINES | 177,75 | 0,00 % | Praxis Precision Medicines prices $525M public offering |
Das Unternehmen SHANGHAI JUNSHI BIOSCIENCES CO LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 2,700 Euro und damit -0,74 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI JUNSHI BIOSCIENCES CO LTD finden Sie auf Wallstreet Online.